PolyTherics expands collaboration with Biocompatibles International

Under the terms of the collaboration agreement, PolyTherics will explore the biological effects on proteins of Biocompatibles’s proprietary phosphorylcholine drug delivery technology. This new study builds on the companies’s established success in applying their respective technologies to the development of protein-based products.

PolyTherics has also granted Biocompatibles an option to develop and commercialize PC-based products utilizing PolyTherics’s proprietary linker technology and intellectual property. Upon the exercise of its option and entry into a product commercialisation agreement, Biocompatibles will pay PolyTherics a royalty on net income resulting from PC-based products that utilize PolyTherics’s technology.